Skip to main content

November 2013

 

 

academics

 

Clinical research courses

THYROID DYSFUNCTIONS AND ITS MONITORING

About Authors:
Pathak Namita*, Kothiyal Preeti, Dr. Prashant Mathur
Department of Clinical Pharmacy,
Shri Guru Ram Rai Institute of Technology and Sciences,
Dehradun, Uttarakhand, India, 248001
pathak_namita@ymail.com

{ DOWNLOAD AS PDF }

Abstract
The prevalence of hypothyroidism is three times higher among women than men. The prevalence in an unselect­ed community population of young, middle aged and elderly individuals is about 1.4 percent and the estimated annual incidence rate is one to two per 1,000 women. Surveys of geriatric populations have yielded estimated prevalence rates for overt hypothyroidism of 0.2 percent to 3 percent. The presentation of symptoms in the elderly may be atypical or absent. The prevalence of subclinical hypothyroidism is estimated to be between 4.0–8.5% of the adult US population without known thyroid disease, and the prevalence increases with age. Up to 20% of women over the age of 60 are estimated to have subclinical hypothyroidism. Caucasians are more likely to have subclinical hypothyroidism than non-Caucasians. The risk is highest in those with type I diabetes mellitus, a family history of thyroid disease or head/neck cancers treated with external beam radiation. Other risk factors include previous radioactive iodine treatment or thyroid surgery. Interestingly, about 20% of patients on thyroid medications are both over re­placed and under replaced. Because of the high incidence of thyroid disease, The American Thyroid Association recommends measuring thyroid function on all adults beginning at age 35 years and every 5 years thereafter noting that more frequent screening may be appropriate in high risk groups. The treatment of subclinical hypothyroidism has been controversial but more recent data suggest there are increased risks of ischemic heart disease in untreated patients and that a more aggressive approach to treat­ ment would be appropriate.7 In contrast, subclinical hyperthyroidism has more well understood risks of atrial fibrillation and flutter and so should be more ag­gressively treated.

Opportunity for B.Pharm, MBA @ Evolet Healthcare

"Evolet" is the pioneer in the field of rendering services of outsourcing – in production of pharmaceutical production.

Several openings at Bose Institute for the levels of Faculty Fellow, Assistant Professor, Associate Professor, Professor

Bose Institute, founded in 1917 by Sir Jagadis Chandra Bose, is a premier institution for basic and applied research in Physical and Biological Sciences as well as inter-disciplinary sciences. For a brief introduction to its activities, please visit the institute’s website boseinst.ernet.in

Post: Assistant Professor, Associate Professor, Professor

Admission in Ph.D at MNIT Jaipur

Malaviya National Institute of Technology Jaipur is one of the 30 National Institutes of Technology in India. These Institutes have been created as centers of excellence for higher training, research and development in science, engineering and technology. Established as a College of Engineering College in 1963, the Institute was declared as National Institute of Technology in the year 2002. It was then accorded the status of deemed university with powers to decide its own academic policy, to conduct its own examinations and to award its own degrees.

Application has to be filled online (link available at mnit.ac.in) by 20th November 2013 and printed application form with photograph, photocopy of necessary documents along-with the Demand Draft of Rs. 400/- for General and OBC, Rs. 200/- for SC/ST category in favour of the Registrar, MNIT Jaipur payable at Jaipur should reach respective department latest by 25th November 2013.

Apply to work as Junior Research Fellow, Research Associate in Bose Institute

Bose Institute, Kolkata, invites application on plain paper from the Indian Citizens, for one temporary post of Junior Research Fellow and one temporary post of Research Associate in the DST sponsored project entitled, “Targeted delivery of nanoconjugated methylglyoxal to cancer cells and understanding the bioenergetic difference between normal and malignant cells at the molecular level”, under the guidance of Prof. Manju Ray (PI) and Dr. Kuladip Jana (Co-PI). The project is tenable for three years.

DRUG DESIGNING : A REVIEW

ABOUT AUTHOR:
Muhammed Mujahed
Master’s of Science in Biotechnology.
SRTM University.
mujubiotech2011@rediffmail.com

INTRODUCTION:
Drug design is an integrated developing discipline which portends an era of ‘tailored drug’. It involves the study of effects of biologically active compounds on the basis of molecular interactions in terms of molecular structure or its physico-chemical properties involved. It studies the processes by which the drug produce their effects, how they react with the protoplasm to elicit a particular pharmacological effect or response how they are modified or detoxified, metabolized or eliminated by the organism.

Disposition of drugs in individual region of biosystems is one of the main factors determining the place , mode and intensity of their action . The biological activity may be “positive” as in drug design or “negative” as in toxicology. Thus drug design involves either total innovation of lead  or an optimization of already available lead. These concepts are the building stones up on which the edifice of drug design is built up.

The drug is most commonly an organicsmall  molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of small molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is often referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design.

PRIMARY AMOEBIC MENINGOENCEPHALITIS

ABOUT AUTHOR:
Akshay Rajgaria
Kanak Manjari Institute of Pharmaceutical Sciences
Rourkela, Orissa
akshaykrish2007@gmail.com

ABSTRACT:
Primary amoebic meningoencephalitis (PAM) caused by free-living amoebae Naegleria fowleri is a rare and fatal condition.

Pharma Jobs & Vacancies in September 2013 | Vacancies for B.Pharm, M.Pharm, B.Sc, M.Sc, Pharm.D, D.Pharm, Ph.D

Job for Group Head-Regulatory Affairs in Novartis
University degree in Life Sciences such as veterinary medicine, toxicology, pharmacy, chemistry or other comparable qualifications.

Jobs in Pharmaceutical & Lifescience Industry in August 2013 | Vacancies for B.Pharm, M.Pharm, D.Pharm, M.Sc, B.Sc, Pharm.D, MBBS, MD, Ph.D

Career for M.Pharm, M.Sc in Medical Writing at inVentiv Health
Master’s degree in a life science-related discipline, communications, or related field, with broad-ranging experience as a medical writer in preparing regulatory and commercial documents

Various Pharma Vacancies for B.Pharm, M.Pharm, Pharm.D, B.Sc, M.Sc, MBBS, MD in Pharmaceutical industry & Pharma Institutes in July 2013

Walk in for PG in Pharmacy as Research Associate, Junior Research Fellow in National AIDS Research Institute
Post Graduate Degree in Microbiology / Biotechnology / Virology / Molecular Biology / Pharmacy